JNJ is involved in healthcare research and development, manufacturing, and sales, with a primary focus on human health and well-being. JNJ stock (NYSE:JNJ) is among the best performers in the market.
JNJ Stock Valuation
The four-year average dividend yield for JNJ is 2.60%, and the current dividend yield is 2.73%. Dividends have grown at a CAGR of 5.8% over the last three years and 5.9% over the last five. The corporation has paid dividends for 59 years in a row.
On August 24, 2022, the FDA approved IMBRUVICA(R) (ibrutinib) for the treatment of pediatric patients with chronic graft-versus-host disease (cGVHD). IMBRUVICA became the first FDA-approved therapy for patients suffering from a life-threatening illness due to this approval.
The FDA approval of IMBRUVICA adds another weapon to their arsenal and has the potential to truly make a difference for those faced with this challenging disease, said Susan Stewart, Executive Director of BMT InfoNet.
JNJs net sales increased 3% year on year to $24.02 billion in the fiscal second quarter (ended June 30, 2022). Its gross profit increased by 2.4% yearly to $16.10 billion. Non-GAAP net earnings increased 4.3% from last year to $6.91 billion, while adjusted EPS increased 4.4% to $2.59.
Analysts predict that JNJs revenue will rise marginally year on year to $23.58 billion in the fiscal third quarter (ending September 30, 2022). Its earnings per share (EPS) are expected to rise 6.7% to $2.27 in the fiscal year ending December 31, 2022. In each of the previous four quarters, the company outperformed the consensus EPS estimate.
JNJ stock (NYSE:JNJ) has increased marginally over the last nine months, closing the most recent trading session at $165.39.
JNJs POWR Ratings reflect its strong fundamentals. In our proprietary rating system, the stock has an overall rating of A, which translates to a Strong Buy. The POWR Ratings are calculated by considering 118 different factors, each of which is weighted to an optimal degree.
It received an A in Stability and a B in Growth, Value, and Quality. JNJ stock (NYSE:JNJ) is ranked first in the Medical Pharmaceuticals industry out of 167 stocks.
Featured Image – Megapixl (C) Alexeynovikov
Author: Okoro Chinedu
Market Jar Media Inc.
#170 – 422 Richards Street
Vancouver, BC, Canada
Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Fortune Bulletin journalist was involved in the writing and production of this article.